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Insulin-Mediated Glucose Uptake
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Abstract
Glucose uptake is regulated by several mechanisms, where insulin plays the most 
prominent role. This powerful anabolic hormone regulates the transport of glucose 
into the cell through translocation of glucose transporter from an intracellular pool 
to the plasma membrane mainly in metabolically active tissues like skeletal muscles, 
adipose tissue, or liver (GLUT4). This translocation occurs through multiple steps 
of PI3K/AKT signaling pathway. In this chapter, we will focus on molecular events 
leading to GLUT4 translocation, starting with activation of insulin receptors 
through signaling cascade involving phosphatidylinositol 3-kinase (PI3K) and 
protein kinase B (PKB) and finally, the action of their effectors. We will present 
regulatory mechanisms and modulators of insulin-mediated glucose uptake.
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1. Introduction
Nowadays, when society is leading an increasingly sedentary lifestyle with 
constant access to food without the need for effort, we observe the raising occur-
rence of diseases with metabolic dysregulation. This financial and social burden has 
caused the great need for understanding mechanistic details of metabolic response 
pathways, causes of their impairment, and following consequences. Carbohydrate 
metabolism is mainly related to glucose. Its level should remain in a narrow range 
(4–7 mM) by balancing glucose release into the circulation, its absorption from 
the intestine, the breakdown of stored glycogen in liver, and the uptake of blood 
glucose by peripheral tissues. These processes are regulated by a few metabolic 
hormones with insulin being the most important one.
2. Mechanism of insulin action
2.1 Insulin
Insulin is an anabolic peptide hormone secreted by pancreatic β cells, whose 
mature form arises in two stages [1]. First, preproinsulin is processed via cutting of 
the signal fragment and forming proinsulin [2]. This is followed by the excision of 
the middle fragment (C chain—35 aa), which gives dipeptide made up of two chains 
(A—21 aa, B—30 aa) connected by two disulfide bonds [3]. Insulin is a multitask 
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protein involved, among others, in the regulation of carbohydrate and lipid metab-
olism (Table 1). The most important stimulus for insulin production is a postpran-
dial increase of blood glucose level. By increasing insulin production and its impact 
on effector cells (myocytes, adipocytes, and hepatocytes), glucose transport to the 
inside of the cells gets increased while reducing blood glucose level. This is achieved 
by an increased translocation of the insulin-dependent glucose carriers (GLUT), 
with GLUT-4 being found in skeletal muscle, hepatocytes, and adipocytes [4].
When glucose concentration exceeds 30 mM in the small intestine, glucose 
transport to the inside of the pancreatic β cells is initiated in an insulin-independent 
way via GLUT2 (Figure 1). GLUT2 facilitates transport with a concentration 
gradient. Inside the cell, glucose is converted into glucose-6-phosphate, which 
prevents the equalization of glucose levels and sustained transport to the cell. 
Glucose-6-phosphate enters the glycolysis, which results in the production of ATP 
molecules. As a result of a continuous glucose supply, the level of ATP is constantly 
increasing. This causes an inhibition of the potassium channel with the outflow of 
K+ ions from the cell being blocked. K+ ions concentration increases inside the cell, 
which becomes electropositive until the charges on the membrane are aligned and 
membrane becomes depolarized. Depolarization activates the voltage-dependent 
calcium channel, promoting the influx of Ca2+ ions to the cell. Ca2+ ions activate 
the ryanodine channel located in the membrane of insulin-accumulating vesicles, 
inducing their migration into the cell membrane and releasing their content [5].
2.2 Insulin signaling pathway
Released insulin participates in many metabolic actions, such as glycogen 
deposition in liver and skeletal muscles, a stimulation of lipogenesis and inhibition 
of lipolysis, and repression of gluconeogenesis in liver, but mainly in increased 
glucose uptake through insulin receptor signaling pathway [6]. Signal transmission 
from the blood to the inside of the cell is a complicated and strongly integrated 
process. It begins with binding of the hormone to the insulin receptor (IR), eliciting 
the large protein signal complex formation just below the surface of the cell mem-
brane around IR’s cytoplasmic domains (Figure 2) [7]. IRs are heterotetrameric 
glycoproteins containing two extracellular (α) and two intracellular (β) subunits. 
They occur mainly on the cell surface of metabolically active tissues like muscles, 
liver, and fat. The binding of insulin by extracellular subunits leads to IR dimeriza-
tion, which allows ATP binding to β-subunits [8]. This causes the activation of 
the catalytic domains of tyrosine kinases in the cytoplasm [9]. In the first stage, 
there is an autophosphorylation of the receptor followed by phosphorylation of 
several substrate proteins, where IRS (insulin receptor substrate) proteins seem 
Upregulation Downregulation
Carbohydrate 
metabolism
Glucose uptake via GLUT4
Glycogen synthesis
Glycolysis
Conversion of pyruvate to acetyl CoA
Glycogenolysis
Gluconeogenesis
Lipid metabolism Fatty acids synthesis
Triglycerides synthesis
Cholesterol synthesis
Lipids oxidation
Triglycerides breakdown
Protein metabolism Transcription of proteins involved in 
energy stores generation
Transcription of proteins involved in 
energy stores release
Table 1. 
Metabolic functions of insulin.
3Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake
DOI: http://dx.doi.org/10.5772/intechopen.80402
to be most significant ones. The phosphorylation occurs on tyrosine residues, and 
then, phosphorylated IRS proteins can trigger two major signaling pathways. First 
pathway leads from Ras to mitogen-activated kinases (MAPK), being involved in 
the expression regulation of genes playing a role in cell growth and differentiation. 
Figure 1. 
Insulin release. Glucose is transported into β-cells via GLUT2 in an insulin-independent way with 
concentration gradient. Then, glucose is phosphorylated by glucokinase to glucose-6-phosphate, which allows 
for its inclusion to metabolic processes and ATP production. Raised ATP level triggers accumulation of K+ ions 
along with membrane depolarization. The latter activates Ca2+ channels, leading to increased concentration of 
Ca2+ ions inside the cell and consequent release of insulin from vesicles. For details see text.
Figure 2. 
Insulin signaling pathway. Insulin attaches to insulin receptors triggering its dimerization and intracellular 
autophosphorylation of their tyrosine residues, which constitute an attachment for IRS proteins. These molecules 
also undergo phosphorylation and form a complex with PI3K utilizing SH2 domains. PI3K phosphorylates 
PIP2, which results in PIP3 formation and activation of PDK1/2. AKT gets phosphorylated and activated by 
PDK1/2, subsequently eliciting phosphorylation of AS160. The latter is responsible for GLUT4 translocation to 
cellular membrane and glucose inflow.
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The second one, phosphatidylinositol 3 kinase (PI3K) pathway, elicits AKT/PKB 
kinase phosphorylation, and it is responsible for the metabolic action of insulin.
3. PI3K/AKT pathway
As shown in Figure 2, activation of PI3K/AKT pathway starts with binding of 
IRS proteins via SH2 domains to PI3 kinase regulatory subunits. This results in 
the activation of PI3K that phosphorylates phosphatidylinositol 4,5-biphosphate 
(PIP2) to phosphatidylinositol(3,4,5)-triphosphate (PIP3). This, in turn, leads to 
the activation of PIP3-dependent kinases: PDK-1 and PDK-2 and eventually to the 
activation of AKT/PKB kinase and atypical PKCs [10]. Subsequently, AKT catalyzes 
the phosphorylation of AS160 substrate protein that stimulates the translocation of 
GLUT glucose transporters from the cytoplasmic vesicles onto the cell membrane 
surface and thereby increases the insulin-dependent transport of glucose into the 
cell. GLUT4 occurs mainly in the interior of the nonstimulated cell, due to the 
proper proportion of two actions: slow exocytosis and rapid endocytosis. AS160 
increases GLUT4 exocytosis and inhibition of its endocytosis via its downstream 
target, Rab10, in adipocytes. This results in GLUT4 accumulation in the plasma 
membrane [11]. Besides the activation of insulin-dependent glucose uptake via 
GLUT4, AKT has many intracellular targets and mediates numerous metabolic 
effects. For instance, AKT triggers phosphorylation of glycogen synthase kinase 
3 (GSK3), which leads to stimulation of glycogen synthesis in liver and skeletal 
muscle [12].
4. PI3K/AKT regulation
The PI3K/AKT pathway is under strict control, and its disturbances are the cause 
of many diseases, including primarily insulin resistance. Further knowledge of the 
mechanisms regulating this signaling is one of the most important challenges of 
modern science. Currently, three specific signaling nodes have been distinguished: 
(a) IRS proteins, (b) regulatory-PI3K kinase subunits, and (c) kinase isoform Akt/
PKB [13]. Disturbances of any of these nodes are mainly responsible for the reduc-
tion of the signal transmission efficiency and related diseases.
4.1 IRS protein node
IRS family consists of six proteins (IRS1–6), where two representatives, IRS1 
and IRS2, are crucial in insulin signaling transduction. IRS proteins show tissue-
specific expression and functionality [14]. They have three characteristic domains: 
(a) pleckstrin homology domain at N-terminus, (b) a phosphotyrosine-binding 
domain enabling binding to IR in the center, and (c) several sites of phosphoryla-
tion on tyrosine and serine residues at C-terminus. After tyrosine residues become 
phosphorylated, IRS binds by C-terminus domain to molecules containing an Src-
homology-2 domain (SH2) [15]. IRS-1 and IRS-2 are widely expressed in all tissues, 
playing major roles in the maintenance of energy balance: muscle, liver, fat, and 
pancreatic islets. However, it seems that IRS1 plays the main role in myocytes and 
adipose tissue, while IRS2 is a key player in hepatocytes and islet cells [16, 17].
Generally, there are three ways allowing the regulation of IRS (Figure 3). Crucial 
control occurs mainly by multiple serine and threonine residues, which may be 
phosphorylated by different kinases. The phosphorylation of serine residues may 
inhibit insulin signaling by blocking tyrosine phosphorylation, which is necessary for 
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signal transduction. However, the details of this inhibitory mechanism are still not 
well understood. Indeed, there is a strong correlation among serine phosphorylation, 
decreased tyrosine phosphorylation, and insulin resistance, which is closely related 
to abnormalities within PI3K pathway. Most critical enzymes being able to phos-
phorylate IRS in serine residue are stress-induced kinases like ERK, JNK, and AMPK 
along with inflammatory kinase IKK and other downstream kinases, such as AKT, 
atypical PKC isoforms, mTOR, or S6K [18, 19]. Blockage of IRS causes the reduced 
cell response for stimulation with insulin and formation of insulin resistance, the 
first step toward diabetes. This inhibitory phosphorylation mostly occurs because of 
low-grade inflammation state, which is caused by lipid accumulation [20]. Studies on 
palmitate showed that it significantly decreased the insulin-stimulated Ser phosphor-
ylation of Akt and Tyr phosphorylation of IRS-1 [21]. Some drugs exert similar effect. 
The prominent example is simvastatin, which is commonly used in the prevention 
and treatment of cardiovascular diseases. Simvastatin reduces the phosphorylation of 
insulin-induced IR at Tyr, IRS-1 at Tyr, and AKT at Thr [22, 23]. Therefore, therapy 
with simvastatin or other statins might be a risk factor for the development of insulin 
resistance or diabetes. This effect can be decreased by many natural substances like 
silibinin (principal flavonoid contained in silymarin, a mixture of flavonolignans 
extracted from Silybum marianum seeds). Silibinin prevents PI3K/AKT pathway inhi-
bition by decreasing IRS1 phosphorylation on Tyr [24]. Similar mechanism is typical 
of PTP1B (protein-tyrosine phosphatase 1B), whose overexpression can inactivate the 
whole PI3K pathway [25]. Since this protein was found to be overexpressed in insulin-
sensitive peripheral tissues (fat, muscle) and in hepatic cells during insulin-resistant 
state, searching for PTP1B inhibitors has become an important area of research in the 
treatment of impairment of insulin transmission pathway. FYGL (Fudan-Yueyang 
G. lucidum extract) appears to be a promising substance showing PTP1B inhibitory 
activity with weak cell permeability and bioavailability [26, 27].
IRS function can be also regulated by competitively inhibiting the binding of IR 
to IRS, primarily by proteins containing phosphotyrosine-binding (PTB) domain. 
One of them, NYGGF4, is highly expressed in obese individuals. Studies on skeletal 
myotubes showed the reduced insulin-induced phosphorylation of IRS1 at Tyr 
and Akt phosphorylation at Ser residue without changes in the insulin-stimulated 
tyrosine phosphorylation of IR [28, 29].
Figure 3. 
Overview of three major mechanisms affecting IRS-dependent signal transduction. Signaling via IR may be 
modulated simply by the decreased rate of IRS gene transcription. Second, proteins with PTB domains may 
compete with IRS for binding to phosphotyrosines of IR. Finally, IRS phosphorylation of serine residue is known 
to suppress phosphorylation of its tyrosine, which is indispensable for signal transduction.
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Among other IRS modulatory mechanisms, it is worth mentioning about 
expression regulation of IRS mediated by hyperinsulinemia and other hormones 
[30]. Anjali et al. showed that FSH (follicle stimulating hormone) induces expres-
sion of IRS2 in granulosa cells [31]. Also, some natural medicines like Tangzhiqing 
formula, a mix of five herbs, modulate IRS expression level in HEPG2 cells (IR1 and 
IRS2) and L-6 myotubes (IRS1) [32].
4.2 PI3K kinase subunits
PI3 kinases constitute protein family, which exhibits activity of phosphoryla-
tion of lipids and proteins. They are divided into three groups according to their 
structural features and substrate preferences (Table 2). Members of I class are 
the most crucial in insulin signaling pathway. PI3K-1 are heterodimers made up of 
regulatory and catalytic subunits. The regulatory subunit is generally referred to 
as p85. They all have a similar domain structure: SH3 domain, breakpoint cluster 
region homology (BH), and two SH2 domains with iSH2 (interSH2) domain in 
between [33]. Signaling is initiated by p85 interacting through the SH2 domain with 
IRS phosphotyrosine motif. Subsequently, p85 is joined through its iSH2 domain to 
the adapter binding domain (ABD) of catalytic subunit called p110. Besides ABD, 
p110 also contains Ras-binding domain (RBD), which is involved in interaction with 
Ras protein superfamily, C2 and the helical scaffolding domains, along with kinase 
domain participating in PIP3 formation [34].
p85 protects p110 from degradation by forming a heterodimer. Furthermore, this 
binding allows p110 translocation to the cell membrane, where catalytic subunit is 
able to send a signal via phosphorylation of PIP2 to PIP3, a lipid second messenger. 
Interestingly, p110α is the most prominent one from all PI3K catalytic subunits in 
insulin-dependent pathway [35]. Cells with its deletion exhibit hyperglycemia and 
glucose intolerance [36]. While p110β seems to play a secondary role, its presence is 
necessary for p110α activity and thus maintenance of basal threshold of PIP3 [37, 38]. 
PIP3 is bound by proteins with PH domain such as AKT and PDK1. This critical event 
allows further signal transduction to downstream proteins.
In this control node, a few aspects are taken into account. Firstly, signaling via 
PI3K is critically dependent upon PI3K regulatory subunit with p85 mediating either 
its restriction or promotion. In cells deprived of upstream stimuli, p85 reduces p110 
activity. It is executed through C2 and helical scaffolding domains, which form 
inhibitory contacts with p85. Furthermore, monomeric p85 binds to phosphorylated 
sites of IRS, thus blocking p85-p110 heterodimer attached to IRS [39]. p110, another 
Class Members Catalytic 
subunit
Regulatory 
subunit
Main reaction Reference
Ia PI3Kα
PI3Kβ
PI3Kδ
p110 (α/β/δ) p85α, p55α, 
p50α, p85β, p55γ
PtdIns(4,5)P2 → PtdIns 
(3,4,5)P3
[33]
Ib PI3Kγ p110γ p101
p84/87
PtdIns(4,5)P2 → PtdIns 
(3,4,5)P3
[33]
II PI3K-C2α
PI3K-C2β
PI3K-C2γ
Monomeric PtdIns(4)P → PtdIns 
(3,4)P2
[76]
III PI3K-C3 Vps34 Vps15 PtdIns → PtdIns (3)P3 [77]
Table 2. 
Classification of PI3K family members.
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essential regulatory molecule, undergoes spatial regulation in some types of human 
cancer. Studies on HepG2 cells demonstrated that PAQR3 (progestin and adipoQ 
receptor family member 3) associates with p110α by attracting it to Golgi apparatus, 
a place of PAQR3 exclusive localization. This event inhibits the interaction between 
p85a and p110α [40, 41].
There are two other possible PI3K activation pathways, both being dependent 
on ligand-membrane receptor binding. The first mechanism is based on binding 
the adaptor protein GRB2 to RTK (receptor tyrosine kinase). When GRB2 is already 
attached to GAB protein, it is allowed to bind p85. By contrast, the second way of 
PI3K activation is not dependent on p85 subunit. In this scenario, GRB2 binds to 
SOS, which activates RAS, leading to activation of p110α subunit. In addition, the 
p110β catalytic subunit may be stimulated in a similar, p85-independent way via G 
protein-coupled receptors [42].
Another critical regulatory mechanism is associated with the control of PIP3 
level. There are several well-known inhibitors which dephosphorylate PIP3 
with phosphatase and tensin homolog (PTEN) being the most well-known one. 
Undoubtedly, PTEN is an intriguing protein for research in the context of diseases 
with PI3K signaling impairment. For instance, in adipose tissue, it can be blocked 
by H2S or its precursor, l-cysteine. Diet supplementation of l-cysteine increases 
PIP3 level and mediates the activation of PI3K, resulting in improvement of glucose 
metabolism [43, 44]. Expression level of PTEN is also regulated epigenetically in 
adipocytes via several miRNAs such as miR-21, miR-23a-3p, miR-26a, miR-26b, 
and miR-181a-5p [45–49]. Another widely known PIP3 inhibitor is SHIP (SH2-
containing inositol 5′-phosphatase). SHIP dephosphorylates PIP3 at 5′-inositol posi-
tion (in contrast to PTEN targeting 3′-inositol position) and inhibits AKT primarily 
through regulation of its cellular localization [50].
Last but not least, PI3K dysregulation can be also underlain by gene mutations 
of p110α and p85 subunits or PI3K negative regulators. For instance, loss of func-
tion or deletion of PTEN is known to occur in numerous types of cancer. Therefore, 
enormous attempts are put into research focused on searching compounds targeting 
PI3K. The most common PI3K regulators are Wortmannin (steroid fungal metabo-
lite) and LY294002 (morpholine-containing chemical compound) [51]. Moreover, 
there are multiple members of a new generation of more stable molecules such as 
SF-1126, CAL101, GSK615, XL147, and PF-4989216, which evoke the suppression of 
overactive PI3K signaling particularly in cancer [52].
4.3 Kinase isoform AKT/PKB
AKT (also named PKB) occurs in mammals in three isoforms (AKT1, AKT2, and 
AKT3). Although they share a similar domain structure (N-terminal PH domain, a 
central kinase domain, and C-terminal domain), AKT isoforms exhibit target speci-
ficity and play divergent roles. AKT2 is the most essential in glucose uptake [53].
The PH domain enables AKT to be attracted by PIP3 just as PDK1. After binding 
to PIP3, AKT undergoes conformational changes that allow revealing the phosphor-
ylation site. While they are in nearby, PDK is able to phosphorylate AKT on Thr308. 
Nevertheless, for full activation of AKT (besides AKT3), second phosphorylation 
on Ser residue is necessary (AKT1-Ser473 and Ser-474 AKT2). Ser473 is modified 
by PDK-2/mTORC2 (mammalian target of rapamycin complex 2) [54]. AKT activa-
tion is terminated through the action of PP2 (protein phosphatase 2) and PHLPP 
(PH domain leucine rich repeat phosphatase), which perform dephosphorylation of 
Thr308 and Ser473, respectively [55].
While phosphorylation status of both of these sites is fundamental for AKT 
activity, there is plethora of other posttranslational modifications affecting its 
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performance [56]. For instance, oxidation of Cys124 triggered by PDGF-induced 
(platelet-derived growth factor) ROS leads to the blockage of AKT2 activity [57]. 
Besides PI3K-dependent activation, AKT may be switched on by alternative modula-
tors. Namely, two groups of uncommon AKT activators are distinguished: tyrosine 
kinases (e.g., ACK1, SRC, PTK6) and serine/threonine kinases (e.g., TBK1, IKBKE). 
ACK1, a non-receptor tyrosine kinase, is capable of regulating AKT recruitment to 
the plasma membrane due to AKT phosphorylation on Tyr176, making it prefer-
entially binding to phosphatidic acid—a membrane phospholipid. This elicits AKT 
attachment to plasma membrane even in the presence of some specific PI3K inhibi-
tors. The increase of AKT2 activity occurs in many cancers, which may be underlain 
by auto-activating mutations of ACK1. Another nonreceptor kinase involved in AKT 
regulation is Src. Its action takes place on Tyr315 and 326. By contrast, PTK6 responds 
to epidermal growth factor (EGF), whose overexpression is typical of many cancers, 
via phosphorylating Tyr215 and 326. Modifications triggered by Src and PTK6 are 
resistant to some popular PI3K inhibitors. The second group of AKT activators, Ser/
Thr kinases, modifies Thr195, Ser378, and Ser473 (TBK1), as well as Ser137, Thr308, 
and Ser473 (IKBKE). These alternative activation modes may suggest that under some 
particular conditions, cells can turn on AKT signaling in quick response [58].
Due to the fact that AKT, just like PI3K, is one of the most commonly deregu-
lated molecules in human cancers, AKT inhibitors development constitutes 
an important field of research. Currently tested molecules utilize two major 
mechanisms. First group acts as competitors for ATP-binding site of AKT (e.g., 
GSK690693, GDC-0068, GSK2110183, and GSK2141795). They share features of 
major pharmacophore with minor differences. The second group is composed of 
allosteric AKT inhibitors (e.g., 2,3-diphenylquinoxaline and analogs, alkylphospho-
lipids). Many of these molecules are in clinical trial phase and have a potential in 
the treatment of AKT dysregulations [59].
5. Environmental insulin signaling modulating factors
The relationship between environmental factors like diet, drugs, lifestyle in 
general, and PI3K pathway remains undeniable. Herein, we will discuss major 
agents responsible for PI3K modulation. In terms of mediated effect, they can be 
divided into two types: insulin sensitizing factors and insulin-resistance inducing 
factors. They do not usually affect a specific protein, but through their action, they 
dysregulate the entire pathway and the overall metabolism.
5.1 Factors inducing insulin resistance
Due to the fact that insulin is one of the key regulators of metabolism, it is not 
surprising that the most important factor modulating its action is diet. Impairment 
of PI3K signaling is well known to be connected with obesity. Depending on the 
tissue, the mechanism of obesity-induced insulin resistance seems to differ, but it 
is in general connected with lipid overload. In liver and muscles, the most crucial is 
elevation of FFA level, which is characteristic for the obese. In consequence, toxic 
lipids, mainly ceramides and diacylglycerol (DAG), do accumulate. The increased 
amount of ceramides causes PP2A stimulation, which terminates insulin pathway 
via AKT dephosphorylation. On the other hand, DAG activates PKC isoforms (ε 
and θ) [60]. The latter ones are able to obstruct signaling either by IRS (muscles) 
or IR (liver). PKC isoforms activation leads to increased expression of NFκB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), which takes part 
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in inflammatory cell response. Subsequently, NFκB activates pro-inflammatory 
cytokines and stress-induced serine-threonine kinases like JNK, which are able to 
block insulin signaling pathway via improper IRS phosphorylation. Furthermore, 
the increasing concentration of lipids in the cells leads to the aggregation of toxic 
metabolites derived from the incomplete oxidation, and, as a result,  the elevated 
synthesis of free radicals. This is also correlated with increased activation of stress-
induced kinases. In overall, these events lead to PI3K pathway impairment and the 
emergence of insulin resistance [60–62].
The mechanism of obesity-induced insulin resistance formation in adipose 
tissue is also related to lipid overload but has a different course. It is connected 
to the constant enlargement of adipocytes, which along with dysregulation 
of adipogenesis leads to the introduction of hypoxia. Reduced oxygen supply 
introduces cellular stress response, which includes activation of stress-induced 
kinases, pro-inflammatory cytokines, and tissue infiltration by pro-inflammatory 
macrophages. These events result in low-grade inflammation state characteristic of 
PI3K impairment. Adipose tissue is not only an energy reservoir but also an active 
endocrine organ, which produces hormones called adipocytokines. They are sensors 
of nutritional and metabolic homeostasis. Accumulation of visceral fat and inflam-
mation development alters the secretary profile of adipocytokines. Adipocytes start 
to send pro-inflammatory signals like TNF-α and interleukin1 (IL1). Other typical 
insulin resistance-inducing cytokines are resistin and IL-6, which activate pro-
inflammatory pathways of NFκB and JNK kinase, leading to defective response to 
insulin [63].
5.2 Insulin-sensitizing factors
While prolonged high-calorie diet undeniably leads to insulin resistance, proper 
dietary style can be a sensitizing factor as well. There are many diet supplements 
improving insulin signaling. Herein, we will point out only a few members of this 
enormous group. For instance, glutamine (Gln) supplementation Gln increases the 
expression of key PI3K signaling molecules (PI3K, PDK1, and GLUT4) and pro-
motes AKT phosphorylation, GLUT4 translocation, and glucose uptake in the pres-
ence of insulin during exposure to hyperglycemia [64]. An epidemic of obesity and 
numerous side effects of drugs that increase insulin sensitivity has caused the great 
interest among scientists to search for natural sensitizers. They include dieckol (an 
extract from a brown seaweed), which enhances translocation of GLUT4 in periph-
eral tissues [65]. Another seaweed improving glucose uptake is Gelidium amansii. 
It exhibits antihyperglycemic, antioxidant, and antiobesity effects potentially via 
PI3K/AKT/GLUT4 signaling [66]. Also, carnosol, a compound found in spices such 
as sage or rosemary, increases glucose uptake via GLUT4 [67]. Interestingly, it has 
been proven that 1,25-dihydroxyvitamin D3 (active form of vitamin D3), which 
is mainly provided with food, can improve glucose uptake and has a potential in 
acting as an anti-inflammatory factor [68]. It seems that an alternative for typical 
drugs like metformin or pioglitazone, which cause side effects, may be products 
containing natural substances like Jiangtang Xiaoke granule. The latter is composed 
of 10 herbs, and it can significantly increase the expression of vast PI3K proteins in 
mice even upon hyperglycemia [69].
Components of the diet are not the only ones able to improve the signaling 
via discussed pathway. Studies on rat model demonstrated that long-term caloric 
restriction may enhance AKT2-dependent mechanism for improving insulin-stim-
ulated glucose uptake. Moreover, a lot of research has been carried out to indicate 
that physical exertion has a positive effect on insulin [70–73].
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6. PI3K/AKT pathway impairment
PI3K pathway impairment is related to many diseases, among which the most 
common and worth attention are insulin resistance and numerous types of cancers.
Insulin resistance may be defined as a subnormal glucose response to endog-
enous and/or exogenous insulin. Peripheral tissues are not able to respond to the 
hormone by increasing glucose uptake from the bloodstream. Initially, pancreatic 
β-cells are not harmed yet, and in response to high glucose level, they synthesize 
more and more insulin. However, if this state lasts for a long time, islet cells start to 
overgrow, and deterioration of their function and/or decline of β-cell mass do occur. 
As normalization of glucose level does not occur, cells are becoming more and more 
resistant to insulin simultaneously forming a vicious circle of insulin resistance. The 
most affected tissues are the most metabolically active ones like liver, muscles, and 
fat. Although the pathogenesis of insulin resistance is getting better understood, the 
exact mechanism is still not clear. The causes may be connected to abnormal insulin 
production, but in most cases, the changes in insulin receptors and their substrates 
along with defects in post-receptor signaling play the role.
PI3K pathway is one of the most frequently deregulated signaling pathways in 
human cancers. As it plays an essential role in many biological processes like cell 
survival, proliferation, migration and differentiation, its dysregulation may result 
in tumorigenesis. The most common changes are mutations (PIK3CA, AKT1, and 
PTEN), genes amplification (PIK3CA, AKT1, and AKT2), and loss of expression or 
deletion of the tumor suppressor PTEN [74]. The highest prevalence of mutations 
within PI3K pathway is typical of lung cancer, breast cancer, endometrial cancer, 
and head and neck cancer along with glioblastoma [75].
7. Conclusions
Insulin is the most crucial agent in glucose metabolism. It stimulates glucose 
uptake from the bloodstream to peripheral tissues. Furthermore, it is responsible for 
energy storage through accelerating glycogen synthesis and lipogenesis. In general, 
it promotes cellular events leading to energy storage and represses processes of 
energy release (Figure 4). Insulin action takes place mainly through PI3K pathway 
and results not only in metabolic effects but also in mitotic response. Insulin is also 
Figure 4. 
Critical actions and pathways controlled by insulin.
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involved in phenomena connected with cell survival. Multitasking nature of this 
hormone causes that any abnormality in its signal transmission can result in seri-
ous consequences, such as diabetes and cancer. These two diseases are the scourge 
of the modern world. The steadily increasing percentage of people suffering from 
insulin resistance or full-blown diabetes and the high incidence of cancer have caused 
scientists to focus on seeking therapeutic goals that may contribute to the prevention 
or treatment of these disorders. In insulin-resistance, the main target constitutes 
the improvement of insulin sensitivity. Among common approaches, it is worth to 
highlight two of them: increasing fatty acids oxidation and elongation of IR activa-
tion state by blocking PTP1B activity. Promising therapeutic targets seem to be also 
pro-inflammatory cytokines and other proteins involved in inflammation response. 
On the other hand, cancer cells show mainly hyperactivity of PI3K pathway and 
the increased glucose uptake. Therefore, it seems that blockage of impaired signal 
transduction may contribute to suppression of the growth of the tumor. For this 
reason, intensive search for selective inhibitors or silencers of the insulin pathway are 
underway. Conducting further research may become the basis for the development of 
new methods of prevention and more effective treatment strategies for these diseases.
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